Department of Medicine, University of Cambridge, Box 157, Level 5, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 0QQ, UK.
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Geroscience. 2017 Jun;39(3):273-291. doi: 10.1007/s11357-017-9986-6. Epub 2017 Jun 24.
Human cytomegalovirus (HCMV) encodes numerous proteins and microRNAs that function to evade the immune response and allow the virus to replicate and disseminate in the face of a competent innate and acquired immune system. The establishment of a latent infection by CMV, which if completely quiescent at the level of viral gene expression would represent an ultimate in immune evasion strategies, is not sufficient for lifelong persistence and dissemination of the virus. CMV needs to reactivate and replicate in a lytic cycle of infection in order to disseminate further, which occurs in the face of a fully primed secondary immune response. Without reactivation, latency itself would be redundant for the virus. It is also becoming clear that latency is not a totally quiescent state, but is characterized by limited viral gene expression. Therefore, the virus also needs immune evasion strategies during latency. An effective immune response to CMV is required or viral replication will cause morbidity and ultimately mortality in the host. There is clearly a complex balance between virus immune evasion and host immune recognition over a lifetime. This poses the important question of whether long-term evasion or manipulation of the immune response driven by CMV is detrimental to health. In this meeting report, three groups used the murine model of CMV (MCMV) to examine if the contribution of the virus to immune senescence is set by the (i) initial viral inoculum, (ii) inflation of T cell responses, (iii) or the balance between functionally distinct effector CD4+ T cells. The work of other groups studying the CMV response in humans is discussed. Their work asks whether the ability to make immune responses to new antigens is compromised by (i) age and HCMV carriage, (ii) long-term exposure to HCMV giving rise to an overall immunosuppressive environment and increased levels of latent virus, or (iii) adapted virus mutants (used as potential vaccines) that have the capacity to elicit conventional and unconventional T cell responses.
人巨细胞病毒 (HCMV) 编码多种蛋白质和 microRNAs,这些蛋白质和 microRNAs 的功能是逃避免疫反应,使病毒在面对强大的固有和获得性免疫系统时能够复制和传播。CMV 通过建立潜伏感染,在病毒基因表达完全静止的情况下,这代表了免疫逃避策略的终极目标,但这不足以使病毒终身持续存在和传播。CMV 需要在裂解性感染周期中重新激活和复制,以便进一步传播,这发生在完全成熟的二次免疫反应的情况下。如果没有重新激活,潜伏本身对病毒来说是多余的。现在也越来越清楚,潜伏并不是一种完全静止的状态,而是以有限的病毒基因表达为特征。因此,病毒在潜伏期间也需要免疫逃避策略。宿主需要对 CMV 产生有效的免疫反应,否则病毒复制会导致宿主发病,最终导致宿主死亡。在一生中,病毒的免疫逃避和宿主的免疫识别之间显然存在着复杂的平衡。这就提出了一个重要的问题,即 CMV 驱动的长期免疫逃避或免疫反应的操纵是否对健康有害。在本次会议报告中,三个小组使用鼠巨细胞病毒 (MCMV) 模型研究了 CMV 是否通过以下三个方面对免疫衰老做出贡献:(i) 初始病毒接种量,(ii) T 细胞反应的膨胀,(iii) 或功能不同的效应性 CD4+T 细胞之间的平衡。其他研究 CMV 对人类影响的小组的工作也在讨论之列。他们的工作探讨了是否(i) 年龄和 HCMV 携带,(ii) 长期暴露于 HCMV 导致整体免疫抑制环境和潜伏病毒水平增加,或 (iii) 适应病毒突变体(用作潜在疫苗)会损害对新抗原产生免疫反应的能力,这些突变体具有引发传统和非常规 T 细胞反应的能力。